ArticleOptics express2022
Monolithic 3D phase profile formation in glass for spatial and temporal control of optical waves.
Article in Optics express, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Optical manufacturing technologies play a central role in modern science and engineering. Progress on both subtractive and additive fabrications is transforming the implementation of optical technologies. Despite the recent advances, modern fabrication still faces challenges in the accuracy, dimension, durability, intensity, and wavelength range. Here we present a direct monolithic 3D phase profile formation in glass and demonstrate its versatile applications for high-accuracy spatial and temporal control of optical waves in the extreme wavelength and intensity domains, direct fabrication of microlenses, and in situ aberration correction for refractive components. These advances and flexibilities will provide a new dimension for high-performance optical design and manufacture and enable novel applications in a broad range of disciplines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.